Major Events - Shanghai Industrial Holdings (00363) plans to sell 49% stake in Shanghai Shanshi Medical Beauty Hospital for 73.598 million yuan [1] - Hengrui Medicine (01276) received approval for clinical trial of Rivoceranib tablets [1] - CanSino Biologics (06185) initiated Phase I clinical trial of inhaled tuberculosis vaccine in Indonesia, completing the enrollment of the first subject [1] - Zhonghui Biotech-B (02627) started Phase I clinical trials for quadrivalent and trivalent influenza virus subunit vaccines [1] - Zhiyun Health (09955) signed a service cooperation agreement with JD Health (06618) to expand online sales and service channels for Livermore tablets and other P2M pipeline products [1] - China Resources Land (01109) plans to place shares of China Resources Mixc Lifestyle (01209) to diversify shareholder structure [1] - Shoucheng Holdings (00697) announced investment in Star Motion Era by Beijing Robotics Fund [1] Financial Performance - Tencent Holdings (00700) reported third-quarter revenue and profit growth, with non-IFRS profit attributable to shareholders reaching 70.551 billion yuan [1] - JD Group-SW (09618) reported third-quarter total revenue of 299.059 billion yuan, a year-on-year increase of 14.85% [1] - JD Logistics (02618) reported third-quarter revenue of 55.084 billion yuan, a year-on-year growth of 24.1% [1] - JD Health (06618) reported third-quarter operating profit of 1.243 billion yuan, a year-on-year increase of 125.3% [1] - SMIC (00981) reported third-quarter profit attributable to shareholders of approximately 192 million USD, a quarter-on-quarter increase of 44.7% and a year-on-year increase of 28.9% [1] - Bilibili-W (09626) reported a net profit of 469 million yuan in the third quarter, turning profitable year-on-year, with all core user metrics reaching historical highs [1] - China Pacific Insurance (02601) reported original insurance premium income of 241.322 billion yuan for the first ten months, a year-on-year increase of 9.9% [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has signed a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, offering a vast user base and extensive platform resources [1] - The partnership represents a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Company Strengths - Zhiyun Health is a leading platform in chronic disease management, possessing a unique product pipeline and expertise in patient management [1] - The collaboration leverages the strengths of both companies to enhance patient access to medications and health services [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health, a major player in the Chinese pharmaceutical e-commerce market [1] - The partnership is expected to leverage JD Health's extensive user base and platform resources to promote high-quality and cost-effective medications [1] Group 2: Strategic Implications - This collaboration represents a strong alliance between two leading companies in their respective fields, enhancing the potential for effective promotion of health management solutions [1] - The partnership will facilitate better patient access to medications and health management services, aligning with the growing trend of digital health solutions in China [1]